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Roles of the renin-angiotensin system in autophagy and ischemia/reperfusion (I/R) injury in the kidney
have not been fully characterized. Here we examined the hypothesis that modest activation of the
angiotensin II (Ang II) receptor upregulates autophagy and increases renal tolerance to I/R injury. Sprague
eDawley rats were assigned to treatment with a vehicle or a non-pressor dose of Ang II (200 ng/kg/min)
for 72 h before 30-min renal I/R. LC3-immunohistochemistry showed that Ang II treatment increased
autophagosomes in proximal tubular cells by 2.7 fold. In Ang II-pretreated rats, autophagosomes were
increased by 2.5 fold compared to those in vehicle-treated rats at 4 h after I/R, when phosphorylation of
Akt and S6 was suppressed and ULK1-Ser555 phosphorylation was increased. Serum creatinine and urea
nitrogen levels, incidence of oliguria, and histological score of tubular necrosis at 24 h after I/R were
attenuated by Ang II-pretreatment. In NRK-52E cells, Ang II induced LC3-II upregulation, which was
inhibited by losartan but not by A779. The results indicate that a non-pressor dose of Ang-II promotes
autophagy via ULK1-mediated signaling in renal tubular cells and attenuates renal I/R injury. The AT1
receptor, but not the Mas receptor, contributes to AngeIIeinduced autophagy and presumably also to the
renoprotection.
© 2020 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/lice
nses/by-nc-nd/4.0/).1. Introduction
Acute kidney injury (AKI) is a common complication in patients
receiving intensive medical care. AKI predicts poor clinical out-
comes in both critically ill and non-critically ill patients1,2 and also
increases the future risk of development of chronic kidney disease
(CKD).3 Multiple renal and extra-renal factors are potentially
involved in the development of AKI, but renal ischemia is a leading
cause of AKI.4 Because of the lack of established pharmacological
intervention, the current strategy for preventing postoperative AKIscular, Renal and Metabolic
dicine, S-1, W-16, Chuo-ku,
rmacological Society.
work.
g by Elsevier B.V. on behalf of Japa
d/4.0/).is risk stratification before surgery, perioperative hemodynamic
monitoring and supportive management including glycemic con-
trol and nutrition.5
Accumulating evidence indicates that ischemia/reperfusion (I/
R) induces autophagy in proximal tubular cells in the kidney.6e8
Autophagy precedes apoptosis, and suppression of autophagy ag-
gravates renal dysfunction after I/R, indicating its protective role in
the kidney.6,9e13 Recently, we found that impaired response of
autophagy contributes to aggravation of I/R-induced AKI by type 2
diabetes mellitus and that suppression of SIRT1/AMPK/ULK1
signaling and enhancement of mTORC1 are involved in the
diabetes-induced suppression of autophagy.11 A few earlier studies
suggested that autophagy in the kidney is regulated by the renin-
angiotensin system (RAS). Yadav et al.14 and Seong et al.15 re-
ported that angiotensin II (Ang II) promoted autophagy in cultured
podocytes, in which generation of reactive oxygen species in
mitochondria was involved. Xu et al.16 recently showed that Ang IInese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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2 cells). Ang II-induced cell death was increased by inhibition of
autophagy14,15 and was, conversely, ameliorated by promotion of
autophagy.16 However, roles of the RAS in I/R-induced autophagy
and renal injury have not been clarified fully.
In the present study, we hypothesized that modest activation of
Ang II receptors promotes autophagy in renal tubular cells and
increases renal tolerance to acute I/R injury in vivo. The rationale for
this hypothesis is three-fold. First, a significant role of Ang II
receptor-mediated signaling in the regulation of autophagy has
been shown in non-renal cells,17,18 and Ang II has been reported to
promote autophagy in renal cells in vitro.14,15 Second, protection
afforded by increased autophagic flux in the kidney has been
shown by experiments using I/R6,12 or by mTORC inhibition as an
intervention to promote autophagy.9,10,13,16 Third, a protective ef-
fect of a modest level of Ang II receptor activation on AKI has been
suggested by clinical findings that the use of RAS inhibitors is
associatedwith increased incidence of AKI19 and elevation of serum
creatinine (s-Cre) after procedures using radio-contrast agents.20 To
test our hypothesis, we assessed the effects of administration of a
non-pressor dose of Ang II on autophagy in the kidney and on
tolerance to I/R injury in rats in vivo. In addition, roles of Ang II
receptor subtypes in Ang II-induced autophagy were examined
in vitro by using a rat proximal tubular cell line.
2. Materials and methods
The present study was conducted in strict accordance with the
Guide for the Care and Use of Laboratory Animals published by
National Research Council of the National Academies, USA (2011)
and was approved by the Animal Use Committee of Sapporo
Medical University (#16e024). The methods are described in detail
in On-line Supplement.
2.1. Animals and experiment protocols
2.1.1. Protocol 1
Male SpragueeDawley (SD) rats (9e10 weeks of age) were
randomly divided into a control group and an Ang II group. The
control group received a vehicle (saline) and the Ang II group
received 200 ng/kg/min of Ang II for 72 h subcutaneously by os-
motic minipumps (Alzet) (Fig. 1A). This dose of Ang II was selected
on the basis of results of pilot experiments. As illustrated in Fig. 1A,
48 h after implantation of osmotic minipumps, rats were housed in
metabolic cages (Nalgene Inc.) individually for 24 h. After mea-
surement of blood pressure and heart rate by the tail-cuff method
(BP-98 A; Softron) in a conscious state, rats were anesthetized with
isoflurane and ventilated with a respirator (Harvard Model 683,
Harvard Apparatus). A heparinized saline-filled catheter (PE50) was
inserted into a carotid artery for monitoring of blood pressure and
sampling of blood. Kidneys were removed, and the tissue samples
for biochemical and immunohistochemical analyses were snap-
frozen by liquid nitrogen and stored at 80 C. Samples for histo-
logical analysis were fixed with 10% formaldehyde. The rats were
then euthanized under deep anesthesia.
2.1.2. Protocol 2
SD rats were divided into three groups: a sham-operated and
vehicle-treated group (Vehicle-sham group), a vehicle-treated I/R
group (Vehicle-I/R group), and an Ang II-treated I/R group (Ang II-I/
R group) (Fig. 2A). The vehicle and Ang II were administered as in
protocol 1 before I/R or the sham procedure. Renal I/R was induced
as previously reported.11 Briefly, after 12-h fasting, rats were
anesthetized with isoflurane and ventilated as in protocol 1. The
right kidney was removed and stored as in protocol 1. Next, the left188renal artery was occluded for 30 min and was then reperfused. In
the sham-operated group, the renal pedicle was not occluded. After
reperfusion or the sham procedure, the skinwound was closed and
then the ratswere returned tometabolic cages (Fig. 2A). At 4 or 24 h
after reperfusion, the rats were re-anesthetized, and the left kidney
and blood of each rat were sampled as in protocol 1, and the rats
were then euthanized. In rats assigned to the 24-h reperfusion
protocol, urine volume during 24-h reperfusionwas measured, and
oliguria was defined as excretion of less than 3 ml of urine in
24 h.21,22
2.2. Cell culture and treatment
NRK-52E cells were obtained fromATCC (American Type Culture
Collection) and were cultured in Dulbecco's Modified Eagle Me-
dium supplemented with 5% fetal bovine serum and antibiotics.
NRK-52E cells were assigned to 4 h of treatment with a vehicle or
1 mM Ang II. In separate groups of cells, an inhibitor of autophagy,
bafilomycin A1 (10 nM), an AT1 receptor antagonist, losartan
(1 mM), or a Mas receptor antagonist, A779 (1 mM), were added to
the culture medium 10 min before treatment with the vehicle or
Ang II. During pharmacological treatments, cells were switched to
serum-free Hanks' Balanced Salt solution. The dose of Ang II and
doses of inhibitors in this series of experiments were selected on
the basis of earlier reports and the results of pilot experiments in
which multiple doses were tested for each agent.
2.3. Immunohistological analysis for autophagosomes
Autophagosomes in renal tissues were visualized by immuno-
staining with anti-LC3 antibodies (Cell Signaling Technology,
#12741) as previously reported.11 Hoechst33342 and lotus tetra-
gonolobus lectin (LTL) conjugated with Texas Red (EY Laboratories,
Inc., San Mateo, CA) were used for staining nuclei and proximal
tubular cells, respectively. To quantify autophagosomes, we
randomly selected ten fields in each section, and LC3-positive areas
per field were averaged.
2.4. Histological analysis of renal tubular injury
Renal tubular injury was assessed histologically with Periodic
acid-Schiff (PAS) staining. Ten images of corticomedullary areas
were randomly selected and captured in each kidney sample under
magnification of x200 in light microscopy. The extent of renal
tubular injury was quantified by using the acute tubular necrosis
(ATN) score23,24 with modifications. ATN score was calculated by
two methods. Global ATN score was obtained according to the
percentage of damaged areas in tubules: 0, no damage; 1, <10%; 2,
11e25%; 3, 26e50%; 4, 51e75%; and 5, >75%. In addition, a score
was given for each of four types of tubule damage: cell lysis (full
field), tubular dilation (full field), loss of tubular brush border (field
in proximal tubules excluding cell lysis and tubular dilation) and
cast formation (field in distal tubules excluding cell lysis and
tubular dilation). A score for each type of damage was given ac-
cording to the percentage of damaged areas: 0, no damage; 1, <25%;
2, 26e50%; 3, 51e75%; and 4, >75%.
2.5. Western blotting
Frozen kidney samples were homogenized in ice-cold buffer
(CelLytic™ MT Cell Lysis Reagent, SigmaeAldrich) including
0.5 mmol/L Na3VO4, a protease inhibitor cocktail (Complete mini,
Roche Molecular Biochemicals) and 1 mmol/l phenyl-
methylsulfonyl fluoride. The homogenate was centrifuged at
15,000 g for 15 min at 4 C to obtain the supernatant. In NRK-52E
Fig. 1. (A) Schematic diagram of the experimental design of protocol 1. (B) Representative images of LC3 (green) and the proximal tubular marker lotus tetragonolobus lectin
conjugated with Texas Red (LTL; red) in the kidneys from rats treated with a vehicle or angiotensin II (Ang II). Nuclei were stained with Hoechst33342 (blue, magnification 200 x).
(C) Areas of green puncta were quantified by using image J. N ¼ 50 from 5 kidneys in each group. s.c.: subcutaneous. *p < 0.05 vs. Vehicle. Values are expressed as means ± SEM.
Scale bar, 50 mm.
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buffer (CelLytic M™, Sigma Aldrich) including protease and phos-
phatase inhibitor cocktails (Nacalai Tesque, Inc.) and centrifuged at
13,000 g for 10 min to obtain the supernatant. Protein concentra-
tion was determined using the Bradford assay. Equal amounts of
proteins were electrophoresed on polyacrylamide gels and then
blotted onto PVDF membranes (Millipore). After blocking with a
TBS-T buffer containing 5% nonfat dry milk or 5% BSA, the blots
were incubated with specific antibodies shown in on-line
Supplementary Table S1. Target proteins were analyzed by densi-
tometry using Fusion Solo 7 S with Fusion-Capt software (Vilber
Lourmat).
2.6. Real-time PCR
Total RNA was isolated from frozen tissues and NRK-52E cells by
using an RNeasy Fibrous Tissue Mini Kit and an RNeasy Mini Kit
(Qiagen), respectively. First-strand complementary DNA was syn-
thesized using a SuperScript VILO™ cDNA Synthesis Kit (Life Tech-
nologies, Thermo Fisher Scientific). DNA amplification was carried
out in ABI PRISM7500 (Life Technologies) by using TaqMan Universal
PCR Master Mix. TaqMan gene expression assays used in this study
are shown in on-line Supplementary Table 2. All assays were carried
out in duplicate and by the standard curve method using serial
complementary DNA dilution. b-actin served as an internal control.
The mRNA levels of the target genes (AT1, AT2, andMAS receptors) in
NRK-52E cells relative to those in an adrenal tissue were calculated
as follows: 2DCt [DCt: difference in cycles to the threshold between
adrenal tissue and NRK-52E cells for each gene].1892.7. Statistical analyses
Data are presented as means ± SEM. Statistical significance in
data between two groups was examined by using the unpaired
Student's two-tailed t-test. Differences betweenmultiple treatment
groups were examined by one-way analysis of variance (ANOVA)
and the Tukey post hoc test. Two-way repeated measures ANOVA
and the Tukey post hoc test were used to examine statistical dif-
ferences in data between pre-I/R and 4 h and 24 h after I/R in the
vehicle and Ang II groups. Differences in incidences of oliguria were
examined by the c2-test. For all tests, p < 0.05 was considered
statistically significant. All analyses were performedwith GraphPad
Prism (Version 6.0, Graph Pad Software).
3. Results
3.1. Effects of Ang II infusion on hemodynamic parameters and
autophagy in the kidney
There was no significant difference in systolic, diastolic or mean
blood pressure, heart rate, kidney weight to body weight ratio,
urine volume or urinary protein excretion between the Ang II group
and the Vehicle group at the end of 72-h treatment (Supplementary
Table 3). Body weight was increased by 10% after 72-h Ang II
infusion via volume retention, while such a body weight change
was not observed after the vehicle infusion. Aldosterone-mediated
glomerular hyperfiltration25,26 in the Ang II group and plasma
volume depletion after the surgery in the Vehicle group may have
underlain slightly lower levels of blood urea nitrogen (BUN) and s-
Fig. 2. (A) Schematic diagram of the experimental design of protocol 2. (B) Activation of the angiotensin II (Ang II) receptor protects the kidney from I/R injury. Blood urea nitrogen
(BUN) and serum creatinine (s-Cre) levels that were increased by I/R were partially restored by pretreatment with Ang II. The incidence of oliguria was significantly lower in the Ang
II group than in the vehicle group. *:p < 0.05 vs. Vehicle-sham, y:p < 0.05 vs. Vehicle-I/R. (C) Representative images of PAS staining of renal tissues at 24 h after I/R (magnification
200 x) and acute tubular necrosis (ATN) scores. Global ATN scores and ATN scores for cell lysis, tubular dilatation, loss of brush border and cast formation 24 h after reperfusion in
the vehicle and Ang II groups are shown. s.c.: subcutaneous. *:p < 0.05 vs. Vehicle-I/R, Values are expressed as means ± SEM. Scale bar, 100 mm.
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(Supplementary Table 3). In immunohistochemistry for autopha-
gosomes, LC3 dots, autophagosome signals, in the kidney sections
were increased by 2.7-fold in tubular cells in the Ang II group
compared to those in the Vehicle group (Fig. 1BC), suggesting that
activation of Ang II receptors upregulates autophagy. Significant
effects of 72-h treatment with Ang II on levels of autophagy marker
proteins and autophagy regulatory kinases were not detectable,
except for slight increase in phosphorylated Akt, in total renal ho-
mogenate samples (Supplementary Fig. S1).1903.2. Effects of pretreatment with Ang II on the extent of renal I/R
injury
There was no significant difference in body weight, systolic,
diastolic or mean blood pressure, or heart rate between the
Vehicle-sham group, the Vehicle-I/R group and the Ang II-I/R group
at 24 h after I/R (Supplementary Table 4). The ratio of kidneyweight
to body weight was higher in the Vehicle-I/R and Ang II-I/R groups
than that in the Vehicle-sham group. As shown in Fig. 2B, BUN and
s-Cre levels were significantly increased in the Vehicle-I/R group
H. Sugawara, N. Moniwa, A. Kuno et al. Journal of Pharmacological Sciences 145 (2021) 187e197compared to those in the Vehicle-sham group (123.3 ± 4.4 vs.
16.5 ± 2.2mg/dl and 4.25± 0.25 vs. 0.33 ± 0.03mg/dl, respectively),
and the changes were partly suppressed in the Ang II-I/R group
(BUN: 99.2 ± 6.0 mg/dl, s-Cre: 3.11 ± 0.41 mg/dl). The incidence of
oliguria was significantly lower in the Ang II-I/R group than in the
Vehicle-I/R group (20% vs. 60%).
Since the Vehicle-sham group showed an ATN score of zero as
expected, the indices of AKI were compared in the Vehicle-I/R
group and Ang II-I/R group. As shown in Fig. 2C, global ATN score
in the Ang II-I/R group was significantly lower than that in the
Vehicle-I/R group, indicating protection afforded by Ang II. In
comparison of scores of tubular injury subtypes, scores for cell lysis
and for loss of tubular brush border in the Ang II-I/R group were
lower than those in the Vehicle-I/R group.
3.3. Autophagosomes and autophagy-regulating proteins during I/R
In the Vehicle-I/R group, autophagosomes in kidney sections
tended to be increased at 4e24 h after I/R, but the change was not
statistically significant (Fig. 3). Autophagosomes in the Ang II-I/R
group were increased by 7.5-fold before I/R (i.e., after Ang II infu-
sion) and by 2.5-fold 4 h after I/R compared to those in the Vehicle-
I/R group, and then the number of autophagosomes in the Ang II-I/R
group decreased to a level similar to that in the Vehicle-I/R group
24 h after I/R.
Effects of I/R and Ang II on levels of autophagy marker proteins
and autophagy regulatory kinases are shown in Figs. 4e6. LC3-II/
LC3-I ratio peaked at 4 h after I/R in both the Vehicle-I/R and Ang II-
I/R groups (Fig. 4AeC). The level of p62 was increased at 24 h after I/
R in both groups, but the change was much smaller in the Ang II-I/R
group (Fig. 4DE). Protein level of beclin-1 (Fig. 4FG) and level of
AMPK phosphorylation (Fig. 5AB) were not significantly changed at
4 or 24 h after I/R in either the Vehicle-I/R group or Ang II-I/R group.
Phosphorylation of ULK1 at Ser555, one of the AMPK-dependent
phosphorylation sites to activate ULK127 and to promotesFig. 3. Time course of changes in levels of autophagosomes in proximal tubular cells before a
the proximal tubular marker lotus tetragonolobus lectin conjugated with Texas Red (LTL; red
(Pre) and at 4 h (I/R-4h) and 24 h (I/R-24 h) after I/R were analyzed. Nuclei were stained w
using image J. N ¼ 50 from 5 kidneys in each group. *: p < 0.05 vs. Vehicle-Pre, y: p < 0.05 vs
means ± SEM. Scale bar, 50 mm.
191autophagy,28 was not significantly changed during I/R in the
Vehicle-I/R group, but it was increased 4 h after I/R in the Ang II-I/R
group (Fig. 5CD). In the Vehicle-I/R group, levels of phosphorylated
Akt and S6 peaked at 4 h after I/R and the levels had declined at 24 h
after I/R. Elevation of phosphorylated Akt and S6 levels at 4 and
24 h after I/R was also observed in the Ang II-I/R group, but the
changes at 4 h after I/R were smaller (Fig. 6AeD).
3.4. mRNA levels of the AT1, AT2 and mas receptors in the kidney
after I/R
I/R reduced the mRNA levels of the AT1a receptor and Mas re-
ceptor in kidney tissue by more than 50% in the Vehicle-I/R group
compared with those in the Vehicle-sham group, while the effects
of I/R on the expression of AT1a and Mas receptors were not sta-
tistically significant in the Ang II-treated group (Supplementary
Fig. S2). Expression of AT2 receptor mRNA could not be detected
in renal samples from any of the three treatment groups.
3.5. mRNA levels of the AT1, AT2 and mas receptors and effects of
ang II receptor antagonists on autophagy in NRK-52E cells
The mRNA levels of the AT1 receptor and Mas receptor in NRK-
52E cells were approximately 1.23% and 13.9% of the levels in the
adrenal tissue, a positive control (Supplementary Fig. S3A). In
contrast, the AT2 receptor mRNA level was extremely low (0.08% of
that in the adrenal tissue), and its level was not changed by treat-
ment with losartan (1 mM) regardless of Ang II treatment
(Supplementary Fig. S3B).
Treatment with Ang II (1 mM) significantly increased the protein
expression of LC3-II and the LC3-II/LC3-I ratio in NRK-52 E cells
(Fig. 7A). Treatment with bafilomycin A1 further increased the LC3-
II level in Ang II-treated cells (Fig. 7B), suggesting that the increase
in LC3-II protein by Ang II reflects increased autophagic flux. Since
anti- Ser555-phospho-ULK1 antibodies did not work in NRK-52End 4 h and 24 h after I/R. (A) Representative images of (time course of) LC3 (green) and
) in the kidneys of vehicle-treated and Ang II-treated rats. Renal tissues sampled before
ith Hoechst33342 (magnification 200 x). (B) Areas of green puncta were quantified by
. Vehicle-4h. z: p < 0.05 vs. Ang II-Pre, x: p < 0.05 vs. Ang II-4h, Values are expressed as
Fig. 4. Time course of levels of LC3 (AeC), p62 (D and E) and beclin-1 (F and G) assessed by Western blotting in protocol 2. Pre: before ischemia-reperfusion, 4 h: 4 h after ischemia-
reperfusion, 24 h: 24 h after ischemia-reperfusion. N ¼ 5 in each treatment. a.u.: arbitrary units. *: p < 0.05 vs Pre, y: p < 0.05 vs 4 h. Values are expressed as means ± SEM.
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ULK1-phospho-Ser317, another phosphorylation site by AMPK to
activate ULK1.29 Ang II increased the phosphorylation of ULK1-
Ser317, while phosphorylation levels of Akt and AMPK were not
significantly changed by Ang II (Fig. 7CeE). Losartan, but not the
Mas receptor antagonist A779, abolished the effect of Ang II on LC3-
II protein expression (Fig. 8).
4. Discussion
The present study showed that administration of a non-pressor
dose of Ang II promoted autophagy in renal proximal tubular cells
and significantly enhanced renal tolerance to I/R injury in vivo. The192results of the experiments using NRK-52E cells indicate that Ang II
directly promotes autophagy in proximal tubular cells in an AT1
receptor-dependent manner. These findings support the notion
that a modest level of AT1 receptor activation affords protection of
the kidneys from I/R injury, in which protective upregulation of
autophagy in proximal tubular cells may play a role.
Although clinical benefits of RAS inhibitors in the management
of cardiovascular and renal diseases have been established, exces-
sive inhibition of RAS by dual RAS blockade is potentially detri-
mental, especially in terms of AKI.30e33 A meta-analysis of studies
including 69,027 patients showed that preoperative use of RAS
blockade in patients undergoing cardiac surgery is associated with
a higher risk of AKI.34 Similarly, use of RAS inhibitors was reported
Fig. 5. Time course of levels of phospho-Thr172 and total AMPK (A and B) and phospho-Ser555 and total ULK1 (C and D) assessed by Western blotting in protocol 2. Pre: before
ischemia-reperfusion, 4 h: 4 h after ischemia-reperfusion, 24 h: 24 h after ischemia-reperfusion. N ¼ 5 in each treatment. a.u.: arbitrary units. *p < 0.05 vs Pre. Values are expressed
as means ± SEM.
Fig. 6. Time course of levels of phospho-Ser473 and total Akt (A and B) and phospho-Ser235/236 and total S6 (C and D) assessed by Western blotting in protocol 2. Pre: before
ischemia-reperfusion, 4 h: 4 h after ischemia-reperfusion, 24 h: 24 h after ischemia-reperfusion. N ¼ 5 in each treatment. a.u.: arbitrary units. *p < 0.05 vs Pre. yp < 0.05 vs 4 h.
Values are expressed as means ± SEM.
H. Sugawara, N. Moniwa, A. Kuno et al. Journal of Pharmacological Sciences 145 (2021) 187e197
193
Fig. 7. (A) Changes in protein expression levels of LC3-I and LC3-II caused by Ang II (1 mM for 4 h) in NRK-52E cells in vitro. N ¼ 11 in each treatment. *: p < 0.05 vs Vehicle. (B)
Protein expression levels of LC3-I and LC3-II with or without Ang II or bafilomycin A1 (Baf). N ¼ 3 in each treatment. *p < 0.05 vs Ang II ()/Baf (). yp < 0.05 vs Ang II ()/Baf (þ). z:
p < 0.05 vs Ang II (þ)/Baf (). (CeE) Effects of Ang II on levels of phospho-Thr172 and total AMPK (C), phospho-Ser317 and total ULK1 (D) and phospho-Ser473 and total Akt (E) in
NRK-52E cells in vitro. N ¼ 11 in each treatment in (C) and (E). N ¼ 4 in each treatment in (D). a.u.: arbitrary units. *p < 0.05 vs Vehicle.
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is a report of protective effect of RAS inhibition in preoperative
patients.35 Recently, a clinical benefit of Ang II administration has
been shown for patients with vasodilatory shock.36,37 In the present
study, administration of a non-pressor dose (i.e., 200 ng/kg/min) of
Ang II for 72 h significantly attenuated renal I/R injury in rats
(Fig. 2). In contrast, Jan et al. reported that subcutaneous admin-
istration of Ang II at a dose of 3 mg/kg 10 min before ischemia had
no significant effect on tissue damage score or s-Cre level after 30-
min ischemia/24-hr reperfusion in mice.38 Taken together, the
findings suggest that activation of Ang II receptors before ischemia
affords protection of the kidneys from AKI depending on their
levels of activation and context.
I/R induced downregulation of the expression of AT1 and Mas
receptors (Supplementary Fig. S2) without an effect on the unde-
tectable level of AT2 receptor expression. It is not clear how these
changes in Ang II receptor expression modify various roles of
endogenous Ang II in the kidney after I/R. Interestingly, Mas re-
ceptor activation during reperfusionwas suggested to attenuate I/R
injury in the heart,39 and Leisman et al. recently showed that194impaired AT1 receptor signaling associated with downregulation of
AT1 receptor expression contributes to sepsis-induced AKI via
functional changes in glomerular hemodynamics in rats.40 Thus,
involvement of downregulation of the expression of AT1 and Mas
receptors in I/R-induced AKI might warrant further investigation.
Earlier studies consistently showed an increase in autophagic
flux in proximal tubular cells in the kidney subjected to I/R.6e8,41
Consistent with earlier findings,6e8,38 both autophagosomes in
proximal tubular cells and LC3-II/LC3-I ratio in the tissue were
increased after I/R in the present study (Figs. 3 and 4). Since tissue
samples used for Western blotting were a mixture of different cells
in the kidney, data obtained by the Western blotting cannot be
directly extrapolated to protein levels in proximal renal tubules.
Nevertheless, I/R induced phosphorylation of Akt and S6, reflecting
activation of the Akt-mTORC1 pathway that inhibits autophagy,
and did not cause any change in AMPK and ULK1 phosphorylation
(Figs. 5 and 6). Thus, upregulation of autophagy during I/R in the
present model of AKI is unlikely to be induced by modulation of
Akt-mTORC1 or ULK1-mediated signaling. The upregulated auto-
phagy during I/R was presumably mediated by I/R-induced
Fig. 8. Protein expression levels of LC3-II were significantly decreased by the AT1 receptor antagonist losartan (A) but not by the Mas receptor antagonist A779 (B) in NRK-52E cells
in vitro. N ¼ 12 in each treatment in (A). N ¼ 10 in each treatment in (B). a.u.: arbitrary units. *p < 0.05 vs Vehicle.
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signaling pathways42 and/or by the PINK1/Parkin-mediated
mechanism.43
The present study showed for the first time that administration
of a non-pressor dose of Ang II before ischemia significantly
increased autophagosome formation in renal tubular cells before
and during I/R in vivo (Fig. 3). The increase in autophagosomes at
4 h after I/R in the Ang II-I/R group is unlikely to be a result of
reduced autophagic flux since Ang II caused no change in LC3 and
p62 protein levels (Fig. 4). A significant change in the phosphory-
lation level of Akt, S6 or ULK1 before I/R was not detectable in the
kidney tissues, but there is the possibility that changes in protein
kinases in the tubular cells were masked by changes in other types
of cells in the sample. In fact, Ang II increased ULK1 phosphoryla-
tion and promoted autophagy in NRK cells in vitro (Fig. 8). The
findings in a renal tubular cell line are consistent with the results of
studies showing that Ang II significantly increased autophagy in
cultured podocytes.15,44 Interestingly, Ang II induced ULK1 phos-
phorylation without increased phosphorylation of AMPK in renal
tissues in vivo and NRK-52E cells in vitro, suggesting the involve-
ment of an AMPK-independent mechanism of ULK1 phosphoryla-
tion. In contrast to its no effect before I/R, Ang II pretreatment
attenuated Akt and S6 phosphorylation and augmented ULK1-
Ser555 phosphorylation at 4 h after I/R compared with those in
the vehicle-treated group (Figs. 5 and 6). These findings suggest
that activation of ULK1 mediated promotion of autophagy by Ang II
pretreatment and that attenuation of Akt-mTORC1 signaling after
reperfusion might have been involved as well.
Although the AT1 receptor mediates Ang II-induced autophagy
(Figs. 7 and 8), it is unclear how activation of the AT1 receptor in-
creases phospho-ULK1 levels at Ser555 in the kidney and at Ser317
in NRK-52E cells without changing phosphorylation levels of
AMPK. Miao et al. reported that PKC-a interacts with ULK1 and is
involved in phosphorylation of ULK1 at Ser317 and Ser555.45 Since
Ang II activates PKC-a via the AT1 receptor in proximal tubular
cells,46,47 activated PKC-a may be involved in phosphorylation of195ULK1. On the other hand, it has been reported that phospho-Ser555
ULK1 level and autophagic flux were increased inmouse fibroblasts
lacking dual-specificity protein phosphatase 1 (DUSP1).48 DUSP1
protein level has been reported to be decreased by AT1 receptor-
mediated proteasome activation.49 Therefore, phosphatase-
mediated regulation may also underlie the increases in phospho-
ULK1 levels induced by Ang II.
The notion that autophagy upregulated by I/R in renal tubular
cells affords protection from I/R injury has been supported by the
results of several earlier studies.6,7,9,10,13 Autophagy was shown to
precede cell death, and suppression of autophagy by different in-
terventions, including proximal tubule-specific deletion of Agt5 or
Agt7, aggravated renal dysfunction after I/R.7,10 Conversely, pro-
motion of autophagy by pharmacological agents attenuated I/R
injury.50 We found that a non-pressor dose of Ang II upregulated
autophagy before ischemia and at least 4 h into the reperfusion
period in vivo. Taken together with the results of earlier
studies,6,7,9,10,13,48 the findings suggest that upregulation of auto-
phagy in renal tubular cells contributes to protective effect of Ang II
against I/R injury (Fig. 2), though contribution of other mechanisms
of protection is possible.
There is the possibility that activation of pro-survival signal
pathways via activated AT1 receptors, in addition to promotion of
autophagy, contributed to renal protection afforded by Ang II pre-
treatment. Stimulation of AT1 receptors triggers activation of PI3K/
Akt and ERK signal pathways, which protect various types of cells,
including renal tubular cells, from I/R injury.51 Focusing on changes
in autophagy, we did not examine responses of the pro-survival
signal pathways to Ang II in the present study. However, Li and
Zhuo47 reported the results of detailed analyses of responses of 38
signal molecules in renal tubular cells to 2-week treatment with a
pressor dose or a non-pressor dose of Ang II in SD rats. Interestingly,
there was no significant phosphorylation of Akt1 at Ser473, ERK1-
T202/Y204, or ERK2-T185/Y187 after 2-week infusion of a pressor
dose or non-pressor dose of Ang II, while phosphorylation of PKC-a,
PKC-bII and GSK-3a was upregulated. Since we also used long
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the study by Li and Zhuo,47 we speculate that the PI3K/Akt or ERK
signal pathway did not play a major role in the protective effect of
Ang II pretreatment observed in the present study.
There are limitations in the present study. First, we did not
directly assess the effects of Ang II on renal circulation before and
during I/R. Thus, the involvement of a modified level and/or dis-
tribution of blood flow within the kidney in protection afforded by
Ang II pretreatment remains unclear. Second, since alterations in
autophagy regulatory signaling by Ang II in the kidney in vivowere
examined by using total kidney tissues forWestern blotting and RT-
PCR, data for proteins and for mRNA levels do not necessarily reflect
changes in proximal tubular cells. Third, a causal relationship be-
tween upregulated autophagy and the renoprotection by Ang II has
not been proved by demonstration of elimination of the protection
by inhibition of autophagy. However, autophagy inhibitors have
off-target effects, and earlier studies showed that tubular cell-
specific deletion of Atg5 or Atg7 induced accumulation of
deformed mitochondria and increased vulnerability of the cells to
ischemia/reperfusion injury.7,10 Thus, autophagy inhibitors and
autophagy-deficient mice are not necessarily useful to critically
determine the extent of contribution of autophagy to the renal
protection afforded by angiotensin II pretreatment.
In conclusion, infusion of Ang II at a non-pressor dose upregu-
lates autophagy in renal tubular cells during an early reperfusion
period and significantly suppresses I/R injury in rats. The effect of
Ang II on autophagy appears to be induced by AT1 receptor-
mediated modulation of ULK1 and Akt/mTORC1 signaling during
the early period of reperfusion. The contribution of autophagy-
dependent and -independent mechanisms to the protection affor-
ded by Ang II against I/R injury warrants further investigation.
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Materials and Methods 
 
The present study was conducted in strict accordance with the Guide for the Care and 
Use of Laboratory Animals published by National Research Council of the National 
Academies, USA (2011) and was approved by the Animal Use Committee of Sapporo 
Medical University (#16-024). 
 
Animals and experiment protocols 
Specific pathogen-free male Sprague-Dawley (SD) rats (9-10 weeks of age) were 
maintained in cages with chow and water at libitum. 
Protocol 1: Rats were randomly divided into a control group and an Ang II group.  The 
control group received a vehicle (saline) and the Ang II group received 200 ng/kg/min of 
Ang II (Alomone Labs, Jerusalem, Israel) for 72 h subcutaneously by osmotic minipumps 
(Alzet, Cupertino, CA, USA) (Fig. 1A).  This dose of Ang II was selected on the basis of 
results of pilot experiments showing that 200 ng/kg/min, but not 10 ng/kg/min, of Ang II 
infusion for 72 h increased autophagosomes in proximal renal tubules without a change 
in blood pressure or heart rates.  As illustrated in Fig. 1A, 48 h after implantation of 
osmotic minipumps, rats were housed in metabolic cages (Nalgene Inc., Rochester, 
USA) individually for 24 h.  After measurement of blood pressure and heart rate by the 
tail-cuff method (BP-98A; Softron, Tokyo, Japan) in a conscious state, rats were 
anesthetized with isoflurane and ventilated with a respirator (Harvard Model 683, 
Harvard Apparatus, South Natick, NA).  A heparinized saline-filled catheter (PE50) was 
inserted into a carotid artery for monitoring of blood pressure and sampling of blood.  
Kidneys were removed from the dorsal approach and immediately soaked in ice-cold 
saline and halved for biochemical and histological analyses.  Kidney tissue samples for 
biochemical and immunohistochemical analyses were snap-frozen by liquid nitrogen and 
stored at -80°C, and samples for histological analysis were fixed with 10% formaldehyde.  
The rats were then euthanized under deep anesthesia. 
Protocol 2:  Rats were divided into three groups: a sham-operated and vehicle-treated 
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group (Vehicle-sham group), a vehicle-treated I/R group (Vehicle-I/R group), and an Ang 
II-treated I/R group (Ang II-I/R group) (Fig. 2A).  The vehicle and Ang II were 
administered as in protocol 1 before I/R or the sham procedure.  Renal I/R was induced 
as previously reported (1).  Briefly, after 12-h fasting, rats were anesthetized with 
isoflurane and ventilated as in protocol 1.  Rectal temperature was adjusted to37°C by 
using a heating pad and lamp.  The kidneys were exposed by the dorsal approach in a 
rat placed in the prone position, and the right kidney was removed and stored as in 
protocol 1.  Next, the pedicle of the left kidney was occluded by using a vascular clamp 
for 30 min to induce ischemia and was then reperfused.  In the sham-operated group, 
the pedicle was not occluded.  After reperfusion or the sham procedure, the skin wound 
was closed and then the rats were individually returned to metabolic cages (Nalgene Inc., 
Rochester, USA) (Fig. 2A).  At 4 or 24 h after reperfusion, the rats were re-anesthetized, 
and the left kidney and blood of each rat were sampled as in protocol 1.  The rats were 
then euthanized.  In rats assigned to the 24-h reperfusion protocol, urine volume during 
24-h reperfusion was measured, and oliguria was defined as excretion of less than 3 ml 
of urine in 24 hours (2, 3). 
 
Biochemical analyses of serum samples 
Levels of s-Cre and blood urea nitrogen (BUN) were determined by using an enzymatic 
assay and ultra-violet absorption spectrophotometry, respectively.  Urine protein level 
was determined by the pyrogallol red method. 
 
Cell culture and treatment 
NRK-52E cells were obtained from ATCC (American Type Culture Collection) and were 
cultured in Dulbecco’s Modified Eagle Medium (4.5 g/L glucose) supplemented with 5% 
fetal bovine serum and antibiotics (Antibiotic-Antimycotic Mixed Stock Solution: Penicillin, 
Streptomycin, Amphotericin B, Nacalai Tesque, Inc., Kyoto, Japan).  NRK-52E cells 
were assigned to 4 h of treatment with a vehicle or 1 μM Ang II (Alomone Labs, 
Jerusalem, Israel).  In separate groups of cells, an inhibitor of autophagy, bafilomycin 
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A1 (10 nM), an AT1 receptor antagonist, losartan (1 μM , Tokyo Chemical Industry, Tokyo, 
Japan), or a Mas receptor antagonist, A779 (1 μM, TOCRIS Bioscience, Minneapolis, 
MN, USA), were added to the culture medium 10 min before treatment with the vehicle 
or Ang II.  During pharmacological treatments, cells were switched to serum-free Hanks' 
Balanced Salt solution. 
 
Imunohistological analysis for autophagosomes 
Autophagosomes in renal tissues were visualized by immunostaining with anti-LC3 
antibodies as previously reported (1).  In brief, renal tissue sections were prepared from 
frozen renal samples, fixed with 4% paraformaldehyde, blocked with 5% bovine serum 
albumin in PBS, and permeabilized with 0.3% triton X-100.  The sections were 
incubated with anti-LC3A/B (Cell Signaling Technology, #12741, 1:50) overnight at 4°C 
and then with an Alexa Fluor 488 anti-rabbit IgG antibody (Invitrogen, Waltham, MA) for 
1 h at room temperature.  Hoechst33342 (Dojindo, Kumamoto, Japan) and lotus 
tetragonolobus lectin (LTL) conjugated with Texas Red (EY Laboratories, Inc., San Mateo, 
CA) were used for staining nuclei and proximal tubular cells, respectively.  To quantify 
autophagosomes, we randomly selected ten fields in each section, and LC3-positive 
areas per field were averaged. 
 
Histological analysis of renal tubular injury 
Renal tubular injury was assessed histologically with Periodic acid-Schiff (PAS) staining.  
Ten images of corticomedullary areas were randomly selected and captured in each 
kidney sample under magnification of x200 in light microscopy.  The extent of renal 
tubular injury was quantified by using the acute tubular necrosis (ATN) score (4, 5) with 
modifications.  ATN score was calculated by two methods.  Global ATN score was 
obtained according to the percentage of damaged areas in tubules: 0, no damage; 1, 
<10%; 2, 11-25%; 3, 26-50%; 4, 51-75%; and 5, >75%.  In addition, a score was given 
for each of four types of tubule damage: cell lysis (full field), tubular dilation (full field), 
loss of tubular brush border (field in proximal tubules excluding cell lysis and tubular 
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dilation) and cast formation (field in distal tubules excluding cell lysis and tubular dilation).  
A score for each type of damage was given according to the percentage of damaged 
areas: 0, no damage; 1, <25%; 2, 26-50%; 3, 51-75%; and 4, >75%.  
 
Western blotting 
Frozen tissue samples from rat kidneys were homogenized in ice-cold buffer (CelLyticTM 
MT Cell Lysis Reagent, Sigma-Aldrich, St. Louis, MO) including 0.5 mmol/L Na3VO4, a 
protease inhibitor cocktail (Complete mini, Roche Molecular Biochemicals, Mannheim, 
Germany) and 1 mmol/l phenylmethylsulfonyl fluoride.  The homogenate was 
centrifuged at 15,000 g for 15 min at 4°C to obtain the supernatant.  In NRK-52E cell 
experiments, harvested cells were homogenized in a lysis buffer (CelLytic MTM, Sigma 
Aldrich) including protease and phosphatase inhibitor cocktails (Nacalai Tesque, Inc., 
Kyoto, Japan).  The homogenate was centrifuged at 13,000 g for 10 min to obtain the 
supernatant.  Protein concentration was determined using the Bradford assay.  Equal 
amounts of proteins were electrophoresed on polyacrylamide gels and then blotted onto 
PVDF membranes (Millipore, Bedford, MA).  After blocking with a TBS-T buffer 
containing 5% nonfat dry milk or 5% BSA, the blots were incubated with specific 
antibodies shown in on-line Supplementary Table S1.  Immunoblotted proteins were 
visualized by using an Immobilon Western detection kit (Millipore, Billerica, MA).  Target 
proteins were analyzed by densitometry using Fusion Solo 7S with Fusion-Capt software 
(Vilber Lourmat, Marne-la-Vallee, France). 
 
Real-Time PCR 
Total RNA was isolated from frozen tissues and NRK-52E cells by using an RNeasy 
Fibrous Tissue Mini Kit and an RNeasy Mini Kit (Qiagen, Valencia, CA, USA), 
respectively.  First-strand complementary deoxyribonucleic acid (DNA) was 
synthesized using a SuperScript VILOTM cDNA Synthesis Kit (Life Technologies, Thermo 
Fisher Scientific, Waltham, MA, USA).  DNA amplification was carried out in ABI 
PRISM7500 (Life Technologies) by using TaqMan Universal PCR Master Mix.  TaqMan 
6 
 
gene expression assays used in this study are shown in on-line Supplementary Table 
S2.  All assays were carried out in duplicate and by the standard curve method using 
serial complementary DNA dilution.  β-actin served as an internal control.  The mRNA 
levels of the target genes (AT1, AT2, and MAS receptors) in NRK-52E cells relative to 
those in an adrenal tissue were calculated as follows: 2ΔCt [ΔCt: difference in cycles to 
the threshold between adrenal tissue and NRK-52E cells for each gene]. 
 
Statistical analyses 
Data are presented as means ± SEM.  Statistical significance in data between two 
groups was examined by using the unpaired Student’s two-tailed t-test.  Differences 
between multiple treatment groups were examined by one-analysis of variance (ANOVA) 
and the Tukey post hoc test.  Two-way repeated measures ANOVA and the Tukey post 
hoc test were used to examine statistical differences in data between pre-I/R and 4 h 
and 24 h after I/R in the vehicle and Ang II groups.  Differences in incidences of oliguria 
were examined by the χ2-test.  For all tests, p < 0.05 was considered statistically 
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Figure S1. Changes in autophagy-related proteins caused by Ang II in rats in protocol 
1 assessed by Western blot analysis.  N = 4 in vehicle-treated rats and N = 6 in Ang II-






Figure S2. Expression of mRNA of AT1 and Mas receptors in the kidney 24 hours after 
ischemia-reperfusion assessed by qRT-PCR. *: p<0.05 vs Vehicle-sham. Values are 
expressed as means.  N = 3 in the Vehicle-sham group, N=6 in the Vehicle-I/R and Ang 
II-I/R groups.  a.u.: arbitrary units.  *p<0.05 vs Vehicle. Values are expressed as 






Figure S3. (A) Expression of mRNA of AT1, AT2 and Mas receptors in NRK-52E cells and 
an adrenal gland tissue, a positive control, assessed by qRT-PCR.  N = 6.  Expression 
levels in NRK-52E cells were presented as the percentage of that in the adrenal gland.  
(B) The effect of losartan on AT2 receptor expression in NRK-52E cells.  NRK-52E cells 
were pretreated with vehicle or losartan for 10 min prior to additional treatment with 
vehicle or angiotensin II (Ang II) for 4 hours.  N = 3.  a.u.: arbitrary units.  Values are 







Table S1. Antibodies used in the present study 
Antibodies Source Cat. No. 
Rabbit monoclonal anti-LC3A/B (D3U4C) XP Cell Signaling #12741 
Guinea pig polyclonal anti-p62/SQSTM1 (C-terminus) PROGEN GP62-C 
Rabbit monoclonal anti-Beclin-1 (D40C5) Cell Signaling  #3459 
Rabbit polyclonal anti-phospho-p70S6 Kinase (Thr389) Cell Signaling  #9205 
Rabbit polyclonal anti-p70S6 Kinase Cell Signaling  #9202 
Rabbit polyclonal anti-phospho-Ser2448-mTOR Cell Signaling #2971 
Rabbit polyclonal anti-mTOR Cell Signaling #2972 
Rabbit polyclonal anti-phospho-Ser235/236-S6 Cell Signaling #9205 
Rabbit polyclonal anti-S6 Cell Signaling #9202 
Rabbit polyclonal anti-phospho-Ser473-Akt Cell Signaling #9271 
Rabbit polyclonal anti-Akt Cell Signaling #9272 
Rabbit monoclonal anti-phospho-Thr172-AMPK Cell Signaling #2535 
Rabbit polyclonal anti-AMPK Cell Signaling #2532 
Rabbit monoclonal anti-phospho-Ser555-ULK1 Cell Signaling #5869 
Rabbit monoclonal anti-phospho-Ser317-ULK1 Cell Signaling #37762 
Rabbit monoclonal anti-ULK1(D8H5) Cell Signaling #8054 
Mouse monoclonal anti-vinculin Sigma-Aldrich V9131 






Table S2. TaqMan gene expression assays used in the present study 










Table S3. Physiological and laboratory parameters of rats treated with vehicle and Ang 
II in Protocol 1. 
  Vehicle Ang II p value 
N 5 5 
 
BW (g) at baseline 302±3 299±8 0.70 
Change in BW after infusion (g) 0.6±2.8 27.2±6.5 < 0.01 
Systolic BP (mmHg) 134±6 115±12 0.16 
Diastolic BP (mmHg) 98±8 89±11 0.50 
Mean BP (mmHg) 110±7 93±11 0.20 
Heart rate (bpm) 371±6 375±7 0.68 
Kidney weight/Body weight (mg/g) 3.50±0.13 3.34±0.09 0.37 
Urine volume (ml/24 h) 19.6±4.1 16.8±4.9 0.65 
Urine protein (mg/24 h) 5.37±1.2 5.32±0.6 0.27 
BUN (mg/dl) 15.3±0.8 11.7±0.5 < 0.01 
Serum creatinine (mg/dl) 0.27±0.02 0.22±0.01 < 0.05 
BW; body weight, Ang II; angiotensin II, BP; blood pressure, BUN; blood urea nitrogen. 







Table S4. Physiological and laboratory parameters of rats treated with vehicle and Ang 
II 24 hours after ischemia-reperfusion injury in Protocol 2. 
 
  Vehicle-sham Vehicle-I/R Ang ll-I/R 
N 5 10 10 
Body weight (g) 363±8 348±6 349±7 
Systolic BP (mmHg) 129.6±1.9 118.7±3.8 122.9±4.0 
Diastolic BP (mmHg) 91.8±2.0 86.7±3.9 82.1±3.0 
Mean BP (mmHg) 104.4±2.0 91.4±3.9 92.9±3.7 
Heart rate (bpm) 339.0±8.1 368.7±14.1 365.9±9.2 
Kidney weight/Body weight (mg/g) 3.44±0.08 5.01±0.24* 4.88±0.14* 
Urine volume (ml/24 h) 9.14±1.39 3.85±1.71 5.78±1.76 
BUN (mg/dL) 16.5±2.2 123.3±4.4* 99.2±6.0*, † 
Serum creatinine (mg/dL) 0.33±0.03 4.25±0.25* 3.11±0.41*, † 
I/R; ischemia-reperfusion, Ang II; angiotensin II, BP; blood pressure, BUN; blood urea nitrogen. 
Values are expressed as mean ± SEM. *P<0.05 vs. Sham-Vehicle, †P<0.05 vs. I/R-Vehicle. 
 
 
